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BACKGROUND: In the past 3 decades, a better understanding of gene mutations and their role in carcinogenesis has led to improve-
ment in our ability to treat patients with metastatic disease. The objective of the current study was to determine whether the location
of a driver mutation within an affected gene impacts the biology of metastatic colorectal cancer. METHODS: DNA was collected from
165 randomly selected specimens of patients who underwent margin-negative resection of colorectal liver metastases with curative
intent. Sequenom analysis and Sanger sequencing were used to evaluate mutations in K/NRAS, PIK3CA, BRAF, and TP53. RESULTS:
BRAF mutation was associated with early recurrence and death, whereas no impact of TP53 or PIK3CA mutation was identified. Al-
though K/NRAS mutation was associated with worse survival in this cohort, this difference was no longer evident when those who
had received anti-EGFR therapy were excluded. When stratifying patients according to the exon on which K/NRAS was mutated,
there were dramatic differences in both survival and pathologic features. Exon 4 mutations were associated with large, solitary me-
tastases occurring at long disease-free intervals compared with exon 3 mutations, which presented with small, numerous lesions.
Patients who had exon 4 mutations recurred infrequently and had significantly longer survival compared with those who had wild
type or other mutations. CONCLUSIONS: By using this model of curative-intent, margin-negative resection in patients at high risk of
recurrence, the authors were able to establish a link between mutation location within the K/NRAS gene and the biology of metastat-
ic colorectal cancer. Cancer 2017;123:568-75. VC 2016 American Cancer Society.
KEYWORDS: colorectal metastases, hepatectomy, rat sarcoma (RAS) mutation, surgery, v-Raf murine sarcoma viral oncogene homo-
log B1 (BRAF) mutation.
INTRODUCTION
Colorectal cancer represents the third most common malignancy in men and women in the United States with 135,000
new cases per year. Twenty percent of patients present with metastatic disease, and many more develop distant spread dur-
ing the course of their illness.1 The most common site of metastasis is the liver: nearly 80% of patients who have stage IV
disease have liver metastasis, and the liver is sole site of disease in 40%. Resection of colorectal liver metastases (CRLM) is
associated with 5-year survival rates of 40% to 60%2,3 as well as occasional long-term cures. The 5-year survival rate with
systemic chemotherapy alone for stage IV disease approaches 10% in highly selected patients, requires chronic therapy,
and is typically noncurative.2,4,5 Although risk scores based on clinical and pathologic parameters have been developed to
predict outcomes after hepatic metastasectomy, these prognostic models tend not to impact clinical decision making and
do not translate well across institutions.6 Therefore, novel and effective prognostic biomarkers are of obvious importance.
At the root of the problem is a lack of convincing data connecting the biologic drivers of carcinogenesis to the phenotype
and survival after metastasectomy.
The mitogen-activated protein kinase (MAPK) signaling pathway consists of a series of kinases that, when triggered
by an extracellular signal, results in a downstream cascade influencing cellular proliferation, differentiation, and survival.
In the middle 1980s, it was discovered that mutations in MAPK pathway genes, most notably Kirstin rat sarcoma viral on-
cogene (K/NRAS), were integral to the initiation and progression of up to 50% of colorectal adenocarcinomas.7 Since
then, oncogenic mutations in other genes, including v-Raf murine sarcoma viral oncogene (BRAF)8 and phosphoinositide
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3-kinase catalytic subunit a (PIK3CA),9 have been identi-
fied. Therapies targeting these pathways have been devel-
oped, and RAS mutational status has emerged as a major
predictor of response to anti-epidermal growth factor re-
ceptor (anti-EGFR) therapies.10,11
Controversy exists regarding the impact of MAPK
mutations on recurrence and survival in patients with co-
lorectal cancer. Previous studies investigating the associa-
tion of MAPK mutations with the phenotype of
metastases and impact on survival have been limited by 3
major factors: 1) the inclusion of patients with a wide vari-
ety of tumor burden and stage, 2) failure to account for
differences because of receipt of anti-EGFR therapy, and
3) lack of analysis of less frequently mutated genes and
exons, such as neuroblastoma rat sarcoma viral oncogene
homolog (NRAS) and KRAS exons 3 and 4.
The objective of this study was to assess the impact
of KRAS, NRAS, BRAF, PIK3CA, and tumor protein 53
(TP53) mutations on recurrence and survival in patients
undergoing curative intent complete resection of CRLM.
This population of patients is at high risk of recurrence,
although they present without macroscopic disease, which
reduces disease burden as a confounder.
MATERIALS AND METHODS
Patients
A prospectively maintained database of tissue samples
obtained under an institutional review board-approved
protocol was queried to identify patients who underwent
resection of CRLM. All patients who had formalin-
fixed, paraffin-embedded (FFPE) blocks and matched
frozen tissue available from resected colorectal liver me-
tastases were selected for further analysis. Perioperative
and survival data were collected by review of a prospec-
tively maintained clinical database and supplemented by
a retrospective review of the medical record. Chemother-
apy administration records were queried for administra-
tion of the anti-EGFR inhibitors cetuximab or
panitumumab either before or after surgery. Only
patients who underwent margin-negative (R0), curative-
intent hepatic resection were included. Pathology reports
were used to capture tumor size and number and to con-
firm margin status.
DNA Extraction and Sequencing
Hematoxylin and eosin-stained slides prepared from
FFPE tissue were reviewed by a gastrointestinal patholo-
gist (E.V.) to ensure adequate tumor content (>50%).
Tumors with excessive necrosis were excluded from analy-
sis. Genomic DNA was extracted from colorectal liver me-
tastasis tissue using the QIAmp DNA extraction kit
(Qiagen, Valencia, Calif) according to the manufacturer’s
protocol and was subjected to whole genome amplifica-
tion using the Repli-G Midi kit (Qiagen). The quality of
whole genome-amplified DNA was verified by polymer-
ase chain reactions using 2 control amplicons. The mass
array-based iPLEX assay (Sequenom, San Diego, Calif)
was used to detect mutations in KRAS (codons 12, 13, 22,
61, 117, and 146), NRAS (codons 12, 13, and 61), BRAF
(codon 600), and PIK3CA (codons 345, 420, 542, 545,
546, 1043, and 1047), as previously described.12,13 All
mutations were confirmed by repeat iPLEX assay or Sang-
er sequencing. TP53 mutations were assessed by routine
Sanger sequencing.
Statistical Analysis
Nominal variables were evaluated using 2-tailed chi-
square or Fisher exact tests, as appropriate. Continuous
variables were assessed with univariate logistic regression
for parametric values and the Wilcoxon rank-sum test
for nonparametric values. Kaplan-Meier survival curves
were created to determine differences in time to recur-
rence and survival. Multivariate regression was per-
formed using data that trended toward significance
(P< .10) on univariate analysis and variables that were




After a medical records review of patients who underwent
resection for colorectal cancer metastases between 1992
and 2009, we identified 211 patients who underwent re-
section of CRLM and had FFPE and frozen tissue samples
available for further analysis. To investigate the impact of
mutation status on survival, we excluded 41 patients who
had known residual disease at the completion of operation
to include only those who underwent curative-intent R0
resections. Of the remaining 170 patients, 5 others were
excluded because they died of other causes (n 5 4) or of
an unknown cause (n 5 1)(Fig. 1).
Demographics and Tumor Characteristics
The mean age of the remaining 165 patients was 57.3
years (confidence interval [CI], 55.3-59.2 years), with a
slight predilection toward male gender (55%). This co-
hort consisted of a heavily pretreated group, of which
72% had received preoperative chemotherapy and 20%
had undergone previous liver resection. Key pathologic
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features included a mean tumor size of 4.3 cm (CI, 3.8-
4.7 cm) and a disease-free interval< 1 year (Table 1).
Mutation Status
Of all 165 patients, 50.6% had a single identified muta-
tion, 30% had 2 or more mutations identified, and
19.4% had no identifiable mutation. The most common
mutation was in TP53 (57.5%), followed by K/NRAS
(43%; KRAS, n 5 65; NRAS, n 5 6). Other less frequent
mutations included PIK3CA (12.1%) and BRAF (3%).
The location of mutation in the K/NRAS gene was most
often in exon 2 (codon 12 or 13, including G12D, G12S,
G12V, G13C, G13D; 81.6% of RAS mutations), fol-
lowed by exon 3 (codon 61, including Q61R and Q61H;
10% of RAS mutations), and exon 4 (codon 146, includ-
ing A146T; 8.5% of RAS mutations) (Table 2).
Pathologic and Demographic Details by
Mutation Status
Demographic details, such as age and sex, did not differ
significantly between patients who had different muta-
tions or mutation locations within the gene. There were
also no differences in mutation patterns between patients
who did and did not receive preoperative chemotherapy.
There were no statistically significant differences in patho-
logic features of the metastases (number or size) or lymph
node status of the primary tumor by mutated gene (ie,
wild type vs K/NRAS vs PIK3CA, etc); however, location
of the K/NRAS mutation within the gene was associated
with various pathologic tumor features. Patients who had
tumors with exon 2 mutations (n 5 58) had features simi-
lar to patients without K/NRAS mutation, with a mean
size of 4.17 cm and an average of 2.4 tumors per resection.
Those who had with mutations in exon 3 (n 5 7) had a
significantly greater number of tumors (mean, 4.7
tumors), which tended to be smaller (mean, 3.34 cm) and
occurred at an earlier disease-free interval (measured from
the date of liver resection) after resection of the primary
tumor (mean, 3.4 months). Patients who had mutations
in exon 4 (n 5 6) tended to have larger (mean, 6.7 cm)
solitary tumors that occurred after a longer disease-free in-
terval (mean, 24.7 months) (Fig. 2).
Overall and Recurrence-Free Survival by
Mutation Status
At a median follow-up of 45 months, 49% of patients had
died of disease, 20% remained alive with active disease,
and 31% remained alive with no evidence of disease. The
3-year and 5-year disease-specific survival (DSS) rates for
the whole cohort were 69% and 48%, respectively, and
the 3-year and 5-year recurrence-free survival rates were
30% and 26%, respectively. There were no differences in
5-year DSS between patients who had TP53 and PIK3CA
mutations (5-year DSS, 47% and 50%, respectively) and
Figure 1. This flow chart outlines the selection and exclusion
populations for the studied cohort.
TABLE 1. Patient Characteristics and Pathologic
Variables, n 5 165
Characteristic Value
Age: Mean [CI], y 57.3 [55.3-59.2]
Men: No. (%) 91 (55)
Synchronous disease: No. (%) 30 (18)
Disease-free interval: Mean [CI], mo 8.7 [6.2-11.1]
No. of tumors: Median [range] 2 [1-12]
Tumor size: Mean [CI], cm 4.3 [3.8-4.7]
Preoperative CEA: Mean [CI], ng/mL 81.6 [33.4-129.8]
Preoperative chemotherapy: No. (%) 91 (72)
Previous liver resection: No. (%) 26 (19)
Abbreviations: CEA, carcinoembryonic antigen; CI, confidence interval.
TABLE 2. Mutation Data, N 5 165
Mutation Site No. of Patients(%)
No detected mutation 32 (19.4)
KRAS/NRAS 71 (43)
Exon 2 58 (35.1)
Exon 3 7 (4.2)




Abbreviations: BRAF, v-Raf murine sarcoma viral oncogene homolog B1;
KRAS, Kirstin rat sarcoma viral oncogene homolog; NRAS, neuroblastoma
rat sarcoma viral oncogene homolog; PIK3CA, phosphoinositide 3-kinase
catalytic subunit a; TP53, tumor protein 53.
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those who had no mutations (Fig. 3a,b). Patients who had
BRAF mutations had a significantly shorter 5-year DSS at
20% (Fig. 3c). Patients who had K/NRAS mutations had
worse 3-year and 5-year DSS compared with those who
had no mutations (60% vs 76% and 38% vs 54%, respec-
tively; P< .05) (Fig. 4a). To account for the potential
confounding effect of anti-EGFR therapies, next, we ex-
cluded patients who had received anti-EGFR treatment in
either the preoperative or postoperative periods. Among the
whole cohort of 165 patients, 44 had received either
cetuximab or panitumumab, including 14 patients with
and 30 patients without K/NRAS mutations. When those
patients were excluded from the analysis, the 3-year and
5-year DSS rates of patients who had K/NRAS mutations
were no different from the rates of patients without muta-
tions (Fig. 4c).
Next, we investigated the prognostic impact of dif-
ferent locations of K/NRAS mutations within the gene.
The 6 patients who had mutations in exon 4 had a signifi-
cantly better 5-year DSS (83%) than those who had muta-
tions in exon 2 (35%) and those who had no K/NRAS
mutation (54%; P< .05). There was only 1 death among
these 6 patients at 35 months; the other 5 patients were
alive at 47, 72, 165, 183, and 229 months. The 7 patients
who had mutations in exon 3 had the worst outcomes,
with no patients surviving at 5 years (Fig. 5a). The
Figure 2. Kirstin rat sarcoma viral oncogene homolog/neuro-
blastoma rat sarcoma viral oncogene homolog (K/NRAS) mu-
tation location is associated with varied tumor phenotype.
Patients with exon 4 mutations had (a) larger tumors and (c)
a longer disease free interval compared with those who had
mutations located elsewhere. (b) Exon 3 mutation was asso-
ciated with greater number of tumors.
Figure 3. Kaplan-Meier curves illustrate overall survival for
patients with or without (a) phosphoinositide 3-kinase cata-
lytic subunit a (PIK3CA), (b) tumor protein 53 (P53), and (c)
v-Raf murine sarcoma viral oncogene homolog B1 (BRAF)
mutation (mut) status.
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exclusion of patients who received anti-EGFR therapy
had no impact on these results. A similar pattern was ob-
served for recurrence-free survival: only 1 patient with an
exon 4 mutation had a postoperative recurrence compared
with all of those who had exon 3 mutations. The median
time to recurrence for patients with exon 3 mutations was
12 months, whereas those who had either no mutation or
the more common exon 2 mutations recurred at a median
of time of 20 and 18 months, respectively (Fig. 5b).
To exclude potential confounding, multivariate
analysis was performed in which we included the variables
associated with recurrence-free survival on univariate anal-
ysis as well as those previously identified as potential con-
founders (tumor size and number, disease-free interval,
lymph node status of the primary tumor, previous chemo-
therapy, and preoperative carcinoembryonic antigen
level). Multivariate analysis identified only size of the
metastasis and driver mutation as predictors of 5-year
recurrence-free survival with a risk ratio of 7.73
(CI, 1.3-154; P 5 .02) and 0.33 (CI, 0.15-0.88;P 5 .03)
for RAS exon 4 and exon 3 mutations, respectively, com-
pared with no RAS mutation.
Patterns of Recurrence
The gene and location of mutations were associated with
the pattern of recurrence. Patients who had BRAF muta-
tions recurred in a multifocal pattern, which included the
lung, liver, and peritoneum. Those who had K/NRAS
mutations recurred in the lung and liver with frequencies
similar to those observed in patients who had wild-type K/
NRAS. This contradicts previous reports suggesting that
patients who have K/NRAS mutations more frequently re-
cur with pulmonary metastases.14 When comparing re-
currence patterns by location of K/NRAS mutation,
patients who had exon 2 mutations relapsed in a pattern
similar to that observed in those who had wild-type K/
NRAS, with an equal proportion of liver and lung lesions.
Patients with exon 3 mutations had a more diffuse recur-
rence pattern that included liver, lung, and peritoneal dis-
ease (Fig. 6).
DISCUSSION
Colorectal cancer remains a significant cause of cancer-
related mortality in the United States and worldwide.
Figure 4. Overall survival is illustrated according to Kirstin rat
sarcoma viral oncogene homolog/neuroblastoma rat sarcoma
viral oncogene homolog (K/NRAS) mutation status. (a)
Kaplan-Meier curves indicate a difference in survival accord-
ing to K/NRAS status. (b) Receipt of antiepidermal growth
factor receptor (anti-EGFR) therapy is illustrated according
to mutation status. (c) After the exclusion of those who re-
ceived anti-EGFR therapy, there was no longer a difference in
survival according to K/NRAS status.
Figure 5. (a) Overall survival and (b) recurrence-free survival
are illustrated according to Kirstin rat sarcoma viral oncogene
homolog/neuroblastoma rat sarcoma viral oncogene homo-
log (K/NRAS) mutation location.
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Patients often present with or develop metastatic disease,
most commonly in the liver or lung. Metastasectomy for
stage IV colon cancer has become an important tool in the
treatment of patients who have limited metastatic disease
to the liver or lung and is associated with prolonged
survival and, occasionally, long-term cure.2,15,16 Despite
advancements in preoperative prognostic modeling, we
are still unable to predict clinically relevant differences
in outcome that can dictate therapeutic decision making.6
However, as our insight into the biology of colorectal
cancer improves, so too should our ability to
prognosticate.
One of the most important advancements in our un-
derstanding of colon cancer biology was the discovery that
a large proportion of tumors were driven by mutations lo-
cated in the MAPK pathway, most notably KRAS.7 Since
its discovery, the most clinically relevant finding related to
RAS-mutated tumors has been its ability to determine
eligibility for treatment with anti-EGFR–based therapy.
More recently, RAS mutations have been studied for their
potential to prognosticate recurrence and survival, provid-
ing a link between genetic mutation and biologic
behavior.
Etienne-Grimaldi et al17 identified 93 patients with
stage IV colon cancer who received fluorouracil-based
chemotherapy and sequenced exon 2 of the KRAS gene.
Those investigators identified mutations in 38.7% of
patients and observed no correlation between RAS muta-
tion status and response or survival. Contrary to this,
Span et al18 demonstrated that survival in patients with all
stages of colorectal cancer was significantly longer for
those who had wild-type KRAS compared with KRAS
mutations. Some of these discordant findings may relate
to the way in which mutations in the KRAS gene are iden-
tified. Because a majority of mutations are identified in
exon 2, many researchers and clinical centers only se-
quence this portion of the gene. Recent data have indicat-
ed that mutations in exons 3 and 4 as well as those in the
related NRAS gene occur in an additional 10% of
patients.13 Consequently, some patients who have RAS
mutations are inadvertently grouped with those who do
not have RAS mutations. Little is known about the biolog-
ic significance of various mutation locations within the
RAS gene, although in vitro data suggest variable potential
for activating downstream signaling, which may result in
differing biology.13 Data linking survival and phenotypic
characteristics of tumors to more in-depth mutational
analysis are lacking.
To study this, we chose a population of patients who
had undergone complete resection of CRLM. These
patients, as a group, have heterogeneous outcomes, with
both a high risk of recurrence and the potential for a cure.
The inclusion only of those patients who underwent
curative-intent R0 resection removes the confounder of
disease burden to gain a clearer view of how driver muta-
tions affect the biology of disease. A cohort similar to this
has been the subject of 2 recent studies. Vauthey et al14
used a similar method of mutation capture and investigat-
ed the impact of KRAS mutation on survival and recur-
rence after hepatic metastasectomy. Those authors
reported significantly worse survival among patients who
had KRAS mutations compared with nonmutated con-
trols. One key limitation to their study was that the inci-
dence of KRAS mutation was only 18%, which is far lower
than that reported by other groups. A second study by
Karagkounis et al19 reported similar results, with worse
overall and recurrence-free survival among patients who
had KRAS mutations compared with those who were
Figure 6. The incidence of recurrence location is illustrated
according to (a) the mutated gene and (b) location of muta-
tion on the K/NRAS gene in patients who developed recur-
rent disease. BRAF indicates v-Raf murine sarcoma viral
oncogene homolog B1.
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mutation-free. That study also excluded patients who re-
ceived preoperative anti-EGFR therapy, and analyzed
only exon 2 mutations, and had no capture of NRAS or
exon 3 and 4 mutations. A recent report by Kemeny and
colleagues examined both survival and recurrence patterns
after hepatectomy according to KRAS mutation status and
observed overall worse survival and a distinct pattern of re-
currence. Like previous findings, nonexon 2 mutations
were not routinely captured, and the study included only
patients who had received hepatic arterial-directed che-
motherapy, limiting the interpretation of results.20
In the current study, an analysis of MAPK pathway
mutations in 165 patients who underwent curative-intent
R0 resection of CRLM was undertaken to determine the
prevalence and clinical significance of individual muta-
tions. Sequenom mass spectrometry analysis was used to
identify point mutations in exons 2, 3, and 4 of KRAS and
in exons 2 and 3 of NRAS, BRAF and PIK3CA. Clinical,
pathologic, and mutation data were available for 165
patients with a median follow-up of 45 months. There
were no survival or pathologic differences in patients who
had PIK3CA or TP53 mutations.
Patients with BRAF mutations were uncommon in
this cohort and fared poorly, as previously reported.21,22
They tended to recur early and diffusely, and none were
disease free at 2 years (data not shown). The incidence of
mutation was only 3%, which was significantly lower than
that reported by studies of primary tumors21 but in line
with reports of metastases,12,14,19,23 highlighting the rarity
with which these patients present with resectable disease.
The incidence of K/NRAS mutation in our cohort
was 43%, which was higher than prior studies of hepatic
metastasectomy,14,19 but in line with other reports of met-
astatic lesions.17,18 In our more in-depth investigation of
the K/NRAS gene, approximately 20% of these mutations
occurred in less common locations on exons 3 and 4. This
is important, because these mutations are often excluded
from traditional mutational analysis. When analyzing the
whole cohort, K/NRAS mutation was associated with
more frequent recurrence and worse DSS,20 as we previ-
ously reported. However, after eliminating patients who
had received anti-EGFR therapy before resection or at the
time of recurrence, this difference no longer existed, sug-
gesting that the survival difference may reflect the efficacy
of this therapy for K/NRAS nonmutants.
On the basis of in vitro data, we hypothesized that
the location of a mutation within the K/NRAS gene may
have an impact on tumor biology, recurrence, and surviv-
al. Janakiraman et al13 analyzed cell lines that had KRAS
mutations in either exon 2, 3, or 4. Those authors
observed that mutations in exons 2 and 3 resulted in more
robust downstream signaling and, theoretically, more ma-
lignant potential compared with exon 4 mutations. To
study this in vivo, we grouped patients according to the
site of their K/NRAS mutation. In concert with the in vitro
findings, patients who had mutations in exon 4 had signif-
icantly fewer recurrences and an improved DSS compared
with those who had other sites of mutation. It is notewor-
thy that the patients who had exon 3 mutations fared
poorly, all recurring within 2 years, and none survived
past 4 years. Multivariate regression confirmed these find-
ings, although the small sample size limited the analysis,
as evidenced by the large confidence intervals. Pathologic
features also differed according to mutation location.
Tumors with exon 4 mutations tended to be large and sol-
itary, whereas those with exon 3 mutations were smaller
and more numerous.
As genetic sequencing becomes faster, more reliable,
and affordable, we are able to glean increasing amounts of
information from resected tumors that can improve our
ability to prognosticate and treat. This study reveals an
even greater complexity than previously recognized, in
which not only does the identity of the driver mutation
impact the biology of disease but so too does the location
of that mutation within the gene. Although validation of
these findings is needed before clinical applicability, it is
reasonable to predict that, in the near future, mutation
status will be used in the same way as tumor size and mul-
tiplicity in guiding our decision to pursue increasingly ag-
gressive metastasectomies.
Limitations of this study include its retrospective na-
ture and the single-institution sample. We also focused
only on hotspot mutations, which fails to take into ac-
count the many other mutations present in colon cancer.
It is possible that unrecognized mutations might be acting
in synergy with KRAS mutations to amplify the findings
we observed. Some patients and tumors were excluded be-
cause of poor quality of the slides or excessive tumor ne-
crosis. Finally, because many of these mutations occur
infrequently, in-depth analyses were limited by the low
number of patients in each group, particularly for patients
with exon 3 and 4 K/NRAS mutated tumors.
In conclusion, we have demonstrated an association
between tumor phenotype and specific gene mutations as
well as the location of a mutation within the gene. This
serves as early data to suggest a possible new tool to help
prognosticate outcomes after metastasectomy and to aid
in preoperative patient selection. Further study, including
prospective collection of mutation status and analysis of
larger populations, is needed.
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